Atossa Genetics (ATOS) Stock: Gaining Ahead Of Data


What We’re Seeing From The Stock 

As investors, one of the first things that we learn is that the news moves the market. In this particular case, the news proved to be overwhelmingly positive. After all, there are few bits of information that seem to cause as much excitement among investors as clinical data. So, it’s no surprise to see that Atossa Genetics is making a run for the top this morning. Of course, our partners at Trade Ideas were the first to alert us to the gains. Currently (9:00), ATOS is trading at $0.61 per share after a gain of $0.07 per share or 13.67% thus far today.

Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!

What We’ll Be Watching For Ahead

Moving forward, the CNA Finance team will continue to keep a close eye on ATOS. In particular, we’re interested in following the story surrounding the continued development of oral Endoxifen as this new data could prove to be an incredible catalyst for the stock. Nonetheless, we’ll continue to follow the story and bring the news to you as it breaks!

Never Miss The News Again

Do you want real-time, actionable news delivered to your inbox? Join the CNA Finance mailing list below!

Subscribe Today!

* indicates required


Please enter your comment!
Please enter your name here